Company Information

Company Profile

Avalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Avalo’s pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Latest Presentations


Contact Information

Investor Relations
Avalo Therapeutics

ICR Westwicke
Chris Brinzey
Managing Director
T: 339-970-2843